Prof. Ye Xu 徐烨
Chief Physician, Professor
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and open surgery for colorectal cancer, including liver and lung metastases, ultra-low sphincter-preserving rectal surgery, and diagnosis and treatment of familial colorectal cancer.
Dr. Xu is Chief of Colorectal Surgery at Fudan University Shanghai Cancer Center. Dr. Xu completed a postdoctoral fellowship in surgery at Brigham and Women’s Hospital, Harvard Medical School, in 2002. Research focuses on surgical and perioperative treatment of colorectal cancer, mechanisms and surgical intervention for liver and lung metastases, and hereditary colorectal cancer.
Professional roles
- Vice Chair, Tumor Surgery Professional Committee, Chinese Research Hospital Association
- Standing Committee Member, Colorectal Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Hereditary Tumor Professional Committee, China Anti-Cancer Association
- Chair, Digestive Tract Hereditary Tumor Professional Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Xu Ye). Papers usually list the name as Ye Xu or Xu Y.
Selected publications
153 papers on PubMed matched by name and affiliation; 39 as first or senior author since 2016. Most recent first- or senior-author papers:
- MedComm (2020), 2026 (first author): Fruquintinib Plus FOLFIRI/FOLFOX as Second-Line Therapy in Patients With RAS-Mutant Metastatic Colorectal Cancer: A Multicenter, Open-Label, Single-Arm Phase II Study. PubMed 43005371
- Cell Oncol (Dordr), 2026 (senior author): Distinct clinical and genomic profiles of braf mutation subtypes in Chinese colorectal cancer: a retrospective cohort study with cross-population validation. PubMed 41838250
- J Gastrointest Oncol, 2026 (senior author): Overstaging of the mesorectal fascia following neoadjuvant therapy and its impact on therapeutic management: a single-center retrospective cohort study of 506 mesorectal fascia positive patients. PubMed 41816585
- BMC Cancer, 2024 (senior author): CapeOX as neoadjuvant chemotherapy for locally advanced rectal cancer: might less be more?. PubMed 39385125
- EBioMedicine, 2024 (first author): Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms. PubMed 38691939
- Cancer Lett, 2024 (senior author): LncRNA GAS6-AS1 contributes to 5-fluorouracil resistance in colorectal cancer by facilitating the binding of PCBP1 with MCM3. PubMed 38521199
- J Gastrointest Oncol, 2023 (senior author): Protective effects of palbociclib on colitis-associated colorectal cancer. PubMed 38196536
- Cancer Biol Med, 2023 (senior author): Improving the value of molecular testing: current status and opportunities in colorectal cancer precision medicine. PubMed 38038341
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion